Koninklijke Philips N.V.

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, SEMHF has a market cap of 45.5B. Regarding current trading prices, RYLPF is priced at $25.44, while SEMHF trades at $40.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas SEMHF's P/E ratio is 18.48. In terms of profitability, RYLPF's ROE is +0.09%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, RYLPF is more volatile compared to SEMHF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check SEMHF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, RSMDF has a market cap of 43.3B. Regarding current trading prices, RYLPF is priced at $25.44, while RSMDF trades at $17.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas RSMDF's P/E ratio is 28.67. In terms of profitability, RYLPF's ROE is +0.09%, compared to RSMDF's ROE of +0.24%. Regarding short-term risk, RYLPF is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check RSMDF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, FUJIY has a market cap of 25.4B. Regarding current trading prices, RYLPF is priced at $25.44, while FUJIY trades at $10.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas FUJIY's P/E ratio is 15.04. In terms of profitability, RYLPF's ROE is +0.09%, compared to FUJIY's ROE of +0.08%. Regarding short-term risk, RYLPF is more volatile compared to FUJIY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check FUJIY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, FUJIF has a market cap of 23.9B. Regarding current trading prices, RYLPF is priced at $25.44, while FUJIF trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas FUJIF's P/E ratio is 14.18. In terms of profitability, RYLPF's ROE is +0.09%, compared to FUJIF's ROE of +0.10%. Regarding short-term risk, RYLPF is more volatile compared to FUJIF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check FUJIF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, SMMNY has a market cap of 22.3B. Regarding current trading prices, RYLPF is priced at $25.44, while SMMNY trades at $19.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas SMMNY's P/E ratio is 18.15. In terms of profitability, RYLPF's ROE is +0.09%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, RYLPF is more volatile compared to SMMNY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check SMMNY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, SONVF has a market cap of 15.9B. Regarding current trading prices, RYLPF is priced at $25.44, while SONVF trades at $275.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas SONVF's P/E ratio is 23.43. In terms of profitability, RYLPF's ROE is +0.09%, compared to SONVF's ROE of +0.21%. Regarding short-term risk, RYLPF is more volatile compared to SONVF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check SONVF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, SONVY has a market cap of 15.5B. Regarding current trading prices, RYLPF is priced at $25.44, while SONVY trades at $52.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas SONVY's P/E ratio is 22.79. In terms of profitability, RYLPF's ROE is +0.09%, compared to SONVY's ROE of +0.22%. Regarding short-term risk, RYLPF is more volatile compared to SONVY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check SONVY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CLPBY has a market cap of 13.5B. Regarding current trading prices, RYLPF is priced at $25.44, while CLPBY trades at $6.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CLPBY's P/E ratio is 40.07. In terms of profitability, RYLPF's ROE is +0.09%, compared to CLPBY's ROE of +0.14%. Regarding short-term risk, RYLPF is more volatile compared to CLPBY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check CLPBY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CLPBF has a market cap of 13.5B. Regarding current trading prices, RYLPF is priced at $25.44, while CLPBF trades at $60.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CLPBF's P/E ratio is 44.94. In terms of profitability, RYLPF's ROE is +0.09%, compared to CLPBF's ROE of +0.14%. Regarding short-term risk, RYLPF is less volatile compared to CLPBF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check CLPBF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, SNNUF has a market cap of 12.7B. Regarding current trading prices, RYLPF is priced at $25.44, while SNNUF trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas SNNUF's P/E ratio is 20.76. In terms of profitability, RYLPF's ROE is +0.09%, compared to SNNUF's ROE of +0.12%. Regarding short-term risk, RYLPF is more volatile compared to SNNUF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check SNNUF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, OCPNF has a market cap of 12.3B. Regarding current trading prices, RYLPF is priced at $25.44, while OCPNF trades at $11.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas OCPNF's P/E ratio is 29.42. In terms of profitability, RYLPF's ROE is +0.09%, compared to OCPNF's ROE of +0.09%. Regarding short-term risk, RYLPF is more volatile compared to OCPNF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check OCPNF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, WILYY has a market cap of 8.3B. Regarding current trading prices, RYLPF is priced at $25.44, while WILYY trades at $19.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas WILYY's P/E ratio is 22.59. In terms of profitability, RYLPF's ROE is +0.09%, compared to WILYY's ROE of +0.16%. Regarding short-term risk, RYLPF is more volatile compared to WILYY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check WILYY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, WILLF has a market cap of 7.5B. Regarding current trading prices, RYLPF is priced at $25.44, while WILLF trades at $35.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas WILLF's P/E ratio is 20.37. In terms of profitability, RYLPF's ROE is +0.09%, compared to WILLF's ROE of +0.16%. Regarding short-term risk, RYLPF is more volatile compared to WILLF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check WILLF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, GNGBY has a market cap of 5.4B. Regarding current trading prices, RYLPF is priced at $25.44, while GNGBY trades at $19.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas GNGBY's P/E ratio is 21.33. In terms of profitability, RYLPF's ROE is +0.09%, compared to GNGBY's ROE of +0.08%. Regarding short-term risk, RYLPF is more volatile compared to GNGBY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check GNGBY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, GNGBF has a market cap of 5.1B. Regarding current trading prices, RYLPF is priced at $25.44, while GNGBF trades at $20.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas GNGBF's P/E ratio is 21.56. In terms of profitability, RYLPF's ROE is +0.09%, compared to GNGBF's ROE of +0.08%. Regarding short-term risk, RYLPF is more volatile compared to GNGBF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check GNGBF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, YPHDF has a market cap of 4.8B. Regarding current trading prices, RYLPF is priced at $25.44, while YPHDF trades at $354.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas YPHDF's P/E ratio is 17.78. In terms of profitability, RYLPF's ROE is +0.09%, compared to YPHDF's ROE of +0.38%. Regarding short-term risk, RYLPF is more volatile compared to YPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check YPHDF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CHEOF has a market cap of 4.7B. Regarding current trading prices, RYLPF is priced at $25.44, while CHEOF trades at $72.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CHEOF's P/E ratio is 19.29. In terms of profitability, RYLPF's ROE is +0.09%, compared to CHEOF's ROE of +0.18%. Regarding short-term risk, RYLPF is less volatile compared to CHEOF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check CHEOF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CHEOY has a market cap of 4.7B. Regarding current trading prices, RYLPF is priced at $25.44, while CHEOY trades at $36.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CHEOY's P/E ratio is 19.26. In terms of profitability, RYLPF's ROE is +0.09%, compared to CHEOY's ROE of +0.18%. Regarding short-term risk, RYLPF is more volatile compared to CHEOY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check CHEOY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, NHNKY has a market cap of 2.8B. Regarding current trading prices, RYLPF is priced at $25.44, while NHNKY trades at $8.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas NHNKY's P/E ratio is 15.71. In terms of profitability, RYLPF's ROE is +0.09%, compared to NHNKY's ROE of +0.08%. Regarding short-term risk, RYLPF is more volatile compared to NHNKY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check NHNKY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, AMFPF has a market cap of 2.6B. Regarding current trading prices, RYLPF is priced at $25.44, while AMFPF trades at $12.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas AMFPF's P/E ratio is 33.36. In terms of profitability, RYLPF's ROE is +0.09%, compared to AMFPF's ROE of +0.07%. Regarding short-term risk, RYLPF is more volatile compared to AMFPF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check AMFPF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, AMBBY has a market cap of 2.6B. Regarding current trading prices, RYLPF is priced at $25.44, while AMBBY trades at $10.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas AMBBY's P/E ratio is 35.64. In terms of profitability, RYLPF's ROE is +0.09%, compared to AMBBY's ROE of +0.08%. Regarding short-term risk, RYLPF is more volatile compared to AMBBY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check AMBBY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, AMBFF has a market cap of 2.6B. Regarding current trading prices, RYLPF is priced at $25.44, while AMBFF trades at $9.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas AMBFF's P/E ratio is 35.36. In terms of profitability, RYLPF's ROE is +0.09%, compared to AMBFF's ROE of +0.08%. Regarding short-term risk, RYLPF is more volatile compared to AMBFF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check AMBFF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, GNNDY has a market cap of 2.2B. Regarding current trading prices, RYLPF is priced at $25.44, while GNNDY trades at $45.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas GNNDY's P/E ratio is 53.85. In terms of profitability, RYLPF's ROE is +0.09%, compared to GNNDY's ROE of -0.04%. Regarding short-term risk, RYLPF is more volatile compared to GNNDY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check GNNDY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, OSSFF has a market cap of 2.2B. Regarding current trading prices, RYLPF is priced at $25.44, while OSSFF trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas OSSFF's P/E ratio is 25.55. In terms of profitability, RYLPF's ROE is +0.09%, compared to OSSFF's ROE of +0.10%. Regarding short-term risk, RYLPF is less volatile compared to OSSFF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check OSSFF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, DRWKF has a market cap of 2.1B. Regarding current trading prices, RYLPF is priced at $25.44, while DRWKF trades at $111.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas DRWKF's P/E ratio is 11.79. In terms of profitability, RYLPF's ROE is +0.09%, compared to DRWKF's ROE of +0.10%. Regarding short-term risk, RYLPF is more volatile compared to DRWKF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check DRWKF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, GGNDF has a market cap of 2.1B. Regarding current trading prices, RYLPF is priced at $25.44, while GGNDF trades at $14.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas GGNDF's P/E ratio is 51.25. In terms of profitability, RYLPF's ROE is +0.09%, compared to GGNDF's ROE of -0.04%. Regarding short-term risk, RYLPF is more volatile compared to GGNDF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check GGNDF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, MCRPF has a market cap of 1.9B. Regarding current trading prices, RYLPF is priced at $25.44, while MCRPF trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas MCRPF's P/E ratio is -10.77. In terms of profitability, RYLPF's ROE is +0.09%, compared to MCRPF's ROE of +0.06%. Regarding short-term risk, RYLPF is more volatile compared to MCRPF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check MCRPF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, OSSUY has a market cap of 1.8B. Regarding current trading prices, RYLPF is priced at $25.44, while OSSUY trades at $3.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas OSSUY's P/E ratio is 20.65. In terms of profitability, RYLPF's ROE is +0.09%, compared to OSSUY's ROE of +0.10%. Regarding short-term risk, RYLPF is less volatile compared to OSSUY. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check OSSUY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, DWRKF has a market cap of 1.8B. Regarding current trading prices, RYLPF is priced at $25.44, while DWRKF trades at $543.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, RYLPF's ROE is +0.09%, compared to DWRKF's ROE of N/A. Regarding short-term risk, RYLPF is more volatile compared to DWRKF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check DWRKF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, NHNKF has a market cap of 1.7B. Regarding current trading prices, RYLPF is priced at $25.44, while NHNKF trades at $15.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas NHNKF's P/E ratio is 30.28. In terms of profitability, RYLPF's ROE is +0.09%, compared to NHNKF's ROE of +0.08%. Regarding short-term risk, RYLPF is less volatile compared to NHNKF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check NHNKF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, MEDGF has a market cap of 1.7B. Regarding current trading prices, RYLPF is priced at $25.44, while MEDGF trades at $83.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, RYLPF's ROE is +0.09%, compared to MEDGF's ROE of +0.22%. Regarding short-term risk, RYLPF is more volatile compared to MEDGF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check MEDGF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, BOEUF has a market cap of 1.6B. Regarding current trading prices, RYLPF is priced at $25.44, while BOEUF trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas BOEUF's P/E ratio is 83.30. In terms of profitability, RYLPF's ROE is +0.09%, compared to BOEUF's ROE of +0.22%. Regarding short-term risk, RYLPF is more volatile compared to BOEUF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check BOEUF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, VTRLY has a market cap of 1.5B. Regarding current trading prices, RYLPF is priced at $25.44, while VTRLY trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas VTRLY's P/E ratio is -2.76. In terms of profitability, RYLPF's ROE is +0.09%, compared to VTRLY's ROE of -0.47%. Regarding short-term risk, RYLPF is more volatile compared to VTRLY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check VTRLY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, FDMDF has a market cap of 1.5B. Regarding current trading prices, RYLPF is priced at $25.44, while FDMDF trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas FDMDF's P/E ratio is -8.62. In terms of profitability, RYLPF's ROE is +0.09%, compared to FDMDF's ROE of -9.21%. Regarding short-term risk, RYLPF is less volatile compared to FDMDF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check FDMDF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, MDRSF has a market cap of 1.4B. Regarding current trading prices, RYLPF is priced at $25.44, while MDRSF trades at $115.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas MDRSF's P/E ratio is 135.29. In terms of profitability, RYLPF's ROE is +0.09%, compared to MDRSF's ROE of +0.03%. Regarding short-term risk, RYLPF is more volatile compared to MDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check MDRSF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, DGWPF has a market cap of 1.4B. Regarding current trading prices, RYLPF is priced at $25.44, while DGWPF trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas DGWPF's P/E ratio is 7.62. In terms of profitability, RYLPF's ROE is +0.09%, compared to DGWPF's ROE of +0.10%. Regarding short-term risk, RYLPF is more volatile compared to DGWPF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check DGWPF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, LFTSF has a market cap of 858.1M. Regarding current trading prices, RYLPF is priced at $25.44, while LFTSF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas LFTSF's P/E ratio is 19.50. In terms of profitability, RYLPF's ROE is +0.09%, compared to LFTSF's ROE of +0.02%. Regarding short-term risk, RYLPF is more volatile compared to LFTSF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check LFTSF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, ELEAF has a market cap of 759.8M. Regarding current trading prices, RYLPF is priced at $25.44, while ELEAF trades at $15.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas ELEAF's P/E ratio is 12.31. In terms of profitability, RYLPF's ROE is +0.09%, compared to ELEAF's ROE of +0.17%. Regarding short-term risk, RYLPF is less volatile compared to ELEAF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check ELEAF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, XVIPF has a market cap of 603.2M. Regarding current trading prices, RYLPF is priced at $25.44, while XVIPF trades at $29.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas XVIPF's P/E ratio is 76.60. In terms of profitability, RYLPF's ROE is +0.09%, compared to XVIPF's ROE of +0.03%. Regarding short-term risk, RYLPF is less volatile compared to XVIPF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check XVIPF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, BRSYF has a market cap of 543.2M. Regarding current trading prices, RYLPF is priced at $25.44, while BRSYF trades at $16.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas BRSYF's P/E ratio is 61.59. In terms of profitability, RYLPF's ROE is +0.09%, compared to BRSYF's ROE of +0.12%. Regarding short-term risk, RYLPF is less volatile compared to BRSYF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check BRSYF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, IOBCF has a market cap of 501.5M. Regarding current trading prices, RYLPF is priced at $25.44, while IOBCF trades at $18.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas IOBCF's P/E ratio is 34.90. In terms of profitability, RYLPF's ROE is +0.09%, compared to IOBCF's ROE of +0.10%. Regarding short-term risk, RYLPF is more volatile compared to IOBCF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check IOBCF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, AVMR has a market cap of 494.2M. Regarding current trading prices, RYLPF is priced at $25.44, while AVMR trades at $9.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas AVMR's P/E ratio is -18.34. In terms of profitability, RYLPF's ROE is +0.09%, compared to AVMR's ROE of -0.23%. Regarding short-term risk, RYLPF is more volatile compared to AVMR. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check AVMR's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CALZF has a market cap of 414.5M. Regarding current trading prices, RYLPF is priced at $25.44, while CALZF trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CALZF's P/E ratio is 60.00. In terms of profitability, RYLPF's ROE is +0.09%, compared to CALZF's ROE of +0.12%. Regarding short-term risk, RYLPF is less volatile compared to CALZF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check CALZF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, HYBT has a market cap of 361.4M. Regarding current trading prices, RYLPF is priced at $25.44, while HYBT trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas HYBT's P/E ratio is N/A. In terms of profitability, RYLPF's ROE is +0.09%, compared to HYBT's ROE of +0.02%. Regarding short-term risk, RYLPF is more volatile compared to HYBT. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check HYBT's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CYBQY has a market cap of 333.5M. Regarding current trading prices, RYLPF is priced at $25.44, while CYBQY trades at $1.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CYBQY's P/E ratio is -187.00. In terms of profitability, RYLPF's ROE is +0.09%, compared to CYBQY's ROE of +0.01%. Regarding short-term risk, RYLPF is more volatile compared to CYBQY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check CYBQY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CLVSF has a market cap of 321.8M. Regarding current trading prices, RYLPF is priced at $25.44, while CLVSF trades at $13.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CLVSF's P/E ratio is 22.48. In terms of profitability, RYLPF's ROE is +0.09%, compared to CLVSF's ROE of +0.15%. Regarding short-term risk, RYLPF is less volatile compared to CLVSF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check CLVSF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CSSPF has a market cap of 273.5M. Regarding current trading prices, RYLPF is priced at $25.44, while CSSPF trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CSSPF's P/E ratio is 32.50. In terms of profitability, RYLPF's ROE is +0.09%, compared to CSSPF's ROE of +0.10%. Regarding short-term risk, RYLPF is less volatile compared to CSSPF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check CSSPF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, DMTRF has a market cap of 270.5M. Regarding current trading prices, RYLPF is priced at $25.44, while DMTRF trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas DMTRF's P/E ratio is -112.50. In terms of profitability, RYLPF's ROE is +0.09%, compared to DMTRF's ROE of +0.36%. Regarding short-term risk, RYLPF is less volatile compared to DMTRF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check DMTRF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CYBQF has a market cap of 248.8M. Regarding current trading prices, RYLPF is priced at $25.44, while CYBQF trades at $1.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CYBQF's P/E ratio is -186.50. In terms of profitability, RYLPF's ROE is +0.09%, compared to CYBQF's ROE of +0.00%. Regarding short-term risk, RYLPF is more volatile compared to CYBQF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check CYBQF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, EBRCZ has a market cap of 246.1M. Regarding current trading prices, RYLPF is priced at $25.44, while EBRCZ trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas EBRCZ's P/E ratio is -1.50. In terms of profitability, RYLPF's ROE is +0.09%, compared to EBRCZ's ROE of -1.80%. Regarding short-term risk, RYLPF is more volatile compared to EBRCZ. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check EBRCZ's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, HTLZF has a market cap of 245.1M. Regarding current trading prices, RYLPF is priced at $25.44, while HTLZF trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, RYLPF's ROE is +0.09%, compared to HTLZF's ROE of -0.01%. Regarding short-term risk, RYLPF is more volatile compared to HTLZF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check HTLZF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, IMPZY has a market cap of 229.3M. Regarding current trading prices, RYLPF is priced at $25.44, while IMPZY trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, RYLPF's ROE is +0.09%, compared to IMPZY's ROE of +8.77%. Regarding short-term risk, RYLPF is more volatile compared to IMPZY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check IMPZY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, XVIPY has a market cap of 206M. Regarding current trading prices, RYLPF is priced at $25.44, while XVIPY trades at $6.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas XVIPY's P/E ratio is N/A. In terms of profitability, RYLPF's ROE is +0.09%, compared to XVIPY's ROE of +0.01%. Regarding short-term risk, RYLPF is more volatile compared to XVIPY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check XVIPY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, VMTHF has a market cap of 186.1M. Regarding current trading prices, RYLPF is priced at $25.44, while VMTHF trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas VMTHF's P/E ratio is -3.01. In terms of profitability, RYLPF's ROE is +0.09%, compared to VMTHF's ROE of -0.21%. Regarding short-term risk, RYLPF is more volatile compared to VMTHF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check VMTHF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, DTXMF has a market cap of 180.6M. Regarding current trading prices, RYLPF is priced at $25.44, while DTXMF trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas DTXMF's P/E ratio is -9.52. In terms of profitability, RYLPF's ROE is +0.09%, compared to DTXMF's ROE of -0.74%. Regarding short-term risk, RYLPF is less volatile compared to DTXMF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check DTXMF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, EKDHF has a market cap of 167.9M. Regarding current trading prices, RYLPF is priced at $25.44, while EKDHF trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas EKDHF's P/E ratio is 39.00. In terms of profitability, RYLPF's ROE is +0.09%, compared to EKDHF's ROE of +0.03%. Regarding short-term risk, RYLPF is less volatile compared to EKDHF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check EKDHF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, EAPIF has a market cap of 162.8M. Regarding current trading prices, RYLPF is priced at $25.44, while EAPIF trades at $1.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas EAPIF's P/E ratio is -0.66. In terms of profitability, RYLPF's ROE is +0.09%, compared to EAPIF's ROE of -0.24%. Regarding short-term risk, RYLPF is less volatile compared to EAPIF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check EAPIF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, BRNHF has a market cap of 161.7M. Regarding current trading prices, RYLPF is priced at $25.44, while BRNHF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas BRNHF's P/E ratio is -5.12. In terms of profitability, RYLPF's ROE is +0.09%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, RYLPF is more volatile compared to BRNHF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check BRNHF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, JMDMF has a market cap of 156.4M. Regarding current trading prices, RYLPF is priced at $25.44, while JMDMF trades at $5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas JMDMF's P/E ratio is 83.33. In terms of profitability, RYLPF's ROE is +0.09%, compared to JMDMF's ROE of N/A. Regarding short-term risk, RYLPF is less volatile compared to JMDMF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check JMDMF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, BCCOY has a market cap of 143M. Regarding current trading prices, RYLPF is priced at $25.44, while BCCOY trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas BCCOY's P/E ratio is -0.90. In terms of profitability, RYLPF's ROE is +0.09%, compared to BCCOY's ROE of -0.51%. Regarding short-term risk, RYLPF is more volatile compared to BCCOY. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check BCCOY's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CLLKF has a market cap of 136.8M. Regarding current trading prices, RYLPF is priced at $25.44, while CLLKF trades at $2.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CLLKF's P/E ratio is -0.88. In terms of profitability, RYLPF's ROE is +0.09%, compared to CLLKF's ROE of -0.52%. Regarding short-term risk, RYLPF is less volatile compared to CLLKF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check CLLKF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, AMEUF has a market cap of 120.5M. Regarding current trading prices, RYLPF is priced at $25.44, while AMEUF trades at $5.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, RYLPF's ROE is +0.09%, compared to AMEUF's ROE of -1.90%. Regarding short-term risk, RYLPF is less volatile compared to AMEUF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check AMEUF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, PXMBF has a market cap of 119.9M. Regarding current trading prices, RYLPF is priced at $25.44, while PXMBF trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas PXMBF's P/E ratio is 23.33. In terms of profitability, RYLPF's ROE is +0.09%, compared to PXMBF's ROE of -0.03%. Regarding short-term risk, RYLPF is more volatile compared to PXMBF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check PXMBF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, AVHHL has a market cap of 105M. Regarding current trading prices, RYLPF is priced at $25.44, while AVHHL trades at $0.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas AVHHL's P/E ratio is -2.73. In terms of profitability, RYLPF's ROE is +0.09%, compared to AVHHL's ROE of +3.05%. Regarding short-term risk, RYLPF is less volatile compared to AVHHL. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check AVHHL's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, SOMNF has a market cap of 98.6M. Regarding current trading prices, RYLPF is priced at $25.44, while SOMNF trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas SOMNF's P/E ratio is -45.00. In terms of profitability, RYLPF's ROE is +0.09%, compared to SOMNF's ROE of -0.05%. Regarding short-term risk, RYLPF is more volatile compared to SOMNF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check SOMNF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, RSHUF has a market cap of 91.5M. Regarding current trading prices, RYLPF is priced at $25.44, while RSHUF trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, RYLPF's ROE is +0.09%, compared to RSHUF's ROE of -4.12%. Regarding short-term risk, RYLPF is less volatile compared to RSHUF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check RSHUF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, CKMTF has a market cap of 85.2M. Regarding current trading prices, RYLPF is priced at $25.44, while CKMTF trades at $12.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, RYLPF's ROE is +0.09%, compared to CKMTF's ROE of +2.58%. Regarding short-term risk, RYLPF is more volatile compared to CKMTF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check CKMTF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, SNZZF has a market cap of 78.9M. Regarding current trading prices, RYLPF is priced at $25.44, while SNZZF trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas SNZZF's P/E ratio is -5.58. In terms of profitability, RYLPF's ROE is +0.09%, compared to SNZZF's ROE of -0.38%. Regarding short-term risk, RYLPF is less volatile compared to SNZZF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check SNZZF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, BLOZF has a market cap of 56.4M. Regarding current trading prices, RYLPF is priced at $25.44, while BLOZF trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas BLOZF's P/E ratio is -11.50. In terms of profitability, RYLPF's ROE is +0.09%, compared to BLOZF's ROE of -3.03%. Regarding short-term risk, RYLPF is more volatile compared to BLOZF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check BLOZF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, TLTFF has a market cap of 50.4M. Regarding current trading prices, RYLPF is priced at $25.44, while TLTFF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas TLTFF's P/E ratio is -17.05. In terms of profitability, RYLPF's ROE is +0.09%, compared to TLTFF's ROE of -2.42%. Regarding short-term risk, RYLPF is more volatile compared to TLTFF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check TLTFF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, NVYTF has a market cap of 34.8M. Regarding current trading prices, RYLPF is priced at $25.44, while NVYTF trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas NVYTF's P/E ratio is -0.86. In terms of profitability, RYLPF's ROE is +0.09%, compared to NVYTF's ROE of -1.22%. Regarding short-term risk, RYLPF is more volatile compared to NVYTF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check NVYTF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, RDGL has a market cap of 33.1M. Regarding current trading prices, RYLPF is priced at $25.44, while RDGL trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas RDGL's P/E ratio is -6.71. In terms of profitability, RYLPF's ROE is +0.09%, compared to RDGL's ROE of -1.48%. Regarding short-term risk, RYLPF is less volatile compared to RDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check RDGL's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, ACIXF has a market cap of 31.5M. Regarding current trading prices, RYLPF is priced at $25.44, while ACIXF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas ACIXF's P/E ratio is -2.80. In terms of profitability, RYLPF's ROE is +0.09%, compared to ACIXF's ROE of -1.06%. Regarding short-term risk, RYLPF is more volatile compared to ACIXF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check ACIXF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, POSC has a market cap of 27.4M. Regarding current trading prices, RYLPF is priced at $25.44, while POSC trades at $1.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas POSC's P/E ratio is -5.82. In terms of profitability, RYLPF's ROE is +0.09%, compared to POSC's ROE of -7.67%. Regarding short-term risk, RYLPF is less volatile compared to POSC. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check POSC's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, MKEAF has a market cap of 25.9M. Regarding current trading prices, RYLPF is priced at $25.44, while MKEAF trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, RYLPF's ROE is +0.09%, compared to MKEAF's ROE of +0.50%. Regarding short-term risk, RYLPF is more volatile compared to MKEAF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check MKEAF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, TCLIF has a market cap of 25.1M. Regarding current trading prices, RYLPF is priced at $25.44, while TCLIF trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas TCLIF's P/E ratio is -4.84. In terms of profitability, RYLPF's ROE is +0.09%, compared to TCLIF's ROE of +2.39%. Regarding short-term risk, RYLPF is less volatile compared to TCLIF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check TCLIF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, KBBTF has a market cap of 24.1M. Regarding current trading prices, RYLPF is priced at $25.44, while KBBTF trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, RYLPF's ROE is +0.09%, compared to KBBTF's ROE of N/A. Regarding short-term risk, RYLPF is more volatile compared to KBBTF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check KBBTF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, PYNKF has a market cap of 22.1M. Regarding current trading prices, RYLPF is priced at $25.44, while PYNKF trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas PYNKF's P/E ratio is 3.79. In terms of profitability, RYLPF's ROE is +0.09%, compared to PYNKF's ROE of -3.36%. Regarding short-term risk, RYLPF is less volatile compared to PYNKF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check PYNKF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, EMITF has a market cap of 21.3M. Regarding current trading prices, RYLPF is priced at $25.44, while EMITF trades at $1.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas EMITF's P/E ratio is -7.62. In terms of profitability, RYLPF's ROE is +0.09%, compared to EMITF's ROE of -0.07%. Regarding short-term risk, RYLPF is more volatile compared to EMITF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check EMITF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, DIZTF has a market cap of 18M. Regarding current trading prices, RYLPF is priced at $25.44, while DIZTF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas DIZTF's P/E ratio is -11.16. In terms of profitability, RYLPF's ROE is +0.09%, compared to DIZTF's ROE of -0.52%. Regarding short-term risk, RYLPF is less volatile compared to DIZTF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check DIZTF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, VPTDF has a market cap of 15.9M. Regarding current trading prices, RYLPF is priced at $25.44, while VPTDF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas VPTDF's P/E ratio is -8.47. In terms of profitability, RYLPF's ROE is +0.09%, compared to VPTDF's ROE of +0.78%. Regarding short-term risk, RYLPF is less volatile compared to VPTDF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check VPTDF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, GTHP has a market cap of 15.7M. Regarding current trading prices, RYLPF is priced at $25.44, while GTHP trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas GTHP's P/E ratio is -5.11. In terms of profitability, RYLPF's ROE is +0.09%, compared to GTHP's ROE of +0.71%. Regarding short-term risk, RYLPF is less volatile compared to GTHP. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check GTHP's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, MDXHF has a market cap of 14.4M. Regarding current trading prices, RYLPF is priced at $25.44, while MDXHF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas MDXHF's P/E ratio is -4.40. In terms of profitability, RYLPF's ROE is +0.09%, compared to MDXHF's ROE of +0.62%. Regarding short-term risk, RYLPF is more volatile compared to MDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check MDXHF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, TMDIF has a market cap of 13.9M. Regarding current trading prices, RYLPF is priced at $25.44, while TMDIF trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, RYLPF's ROE is +0.09%, compared to TMDIF's ROE of +8.70%. Regarding short-term risk, RYLPF is less volatile compared to TMDIF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check TMDIF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, ASAPF has a market cap of 13.7M. Regarding current trading prices, RYLPF is priced at $25.44, while ASAPF trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas ASAPF's P/E ratio is -17.50. In terms of profitability, RYLPF's ROE is +0.09%, compared to ASAPF's ROE of -0.15%. Regarding short-term risk, RYLPF is more volatile compared to ASAPF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check ASAPF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, IPDQF has a market cap of 12.1M. Regarding current trading prices, RYLPF is priced at $25.44, while IPDQF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas IPDQF's P/E ratio is -0.59. In terms of profitability, RYLPF's ROE is +0.09%, compared to IPDQF's ROE of -1.65%. Regarding short-term risk, RYLPF is less volatile compared to IPDQF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check IPDQF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, ATBPF has a market cap of 11.4M. Regarding current trading prices, RYLPF is priced at $25.44, while ATBPF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, RYLPF's ROE is +0.09%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, RYLPF is less volatile compared to ATBPF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check ATBPF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, ALRTF has a market cap of 11.4M. Regarding current trading prices, RYLPF is priced at $25.44, while ALRTF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas ALRTF's P/E ratio is -0.44. In terms of profitability, RYLPF's ROE is +0.09%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, RYLPF is more volatile compared to ALRTF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check ALRTF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, LXXGF has a market cap of 11.3M. Regarding current trading prices, RYLPF is priced at $25.44, while LXXGF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, RYLPF's ROE is +0.09%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, RYLPF is more volatile compared to LXXGF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check LXXGF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, PLLWF has a market cap of 8M. Regarding current trading prices, RYLPF is priced at $25.44, while PLLWF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas PLLWF's P/E ratio is -0.66. In terms of profitability, RYLPF's ROE is +0.09%, compared to PLLWF's ROE of -0.99%. Regarding short-term risk, RYLPF is less volatile compared to PLLWF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check PLLWF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, BIEL has a market cap of 7.2M. Regarding current trading prices, RYLPF is priced at $25.44, while BIEL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas BIEL's P/E ratio is N/A. In terms of profitability, RYLPF's ROE is +0.09%, compared to BIEL's ROE of +0.05%. Regarding short-term risk, RYLPF is less volatile compared to BIEL. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check BIEL's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, QLIS has a market cap of 5.5M. Regarding current trading prices, RYLPF is priced at $25.44, while QLIS trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas QLIS's P/E ratio is 2.22. In terms of profitability, RYLPF's ROE is +0.09%, compared to QLIS's ROE of -0.15%. Regarding short-term risk, RYLPF is more volatile compared to QLIS. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check QLIS's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, RHNMF has a market cap of 5.4M. Regarding current trading prices, RYLPF is priced at $25.44, while RHNMF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, RYLPF's ROE is +0.09%, compared to RHNMF's ROE of +15.91%. Regarding short-term risk, RYLPF is less volatile compared to RHNMF. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check RHNMF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, PMEDF has a market cap of 5.2M. Regarding current trading prices, RYLPF is priced at $25.44, while PMEDF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas PMEDF's P/E ratio is -2.52. In terms of profitability, RYLPF's ROE is +0.09%, compared to PMEDF's ROE of +1.24%. Regarding short-term risk, RYLPF is more volatile compared to PMEDF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check PMEDF's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, ADMT has a market cap of 4.7M. Regarding current trading prices, RYLPF is priced at $25.44, while ADMT trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas ADMT's P/E ratio is -6.90. In terms of profitability, RYLPF's ROE is +0.09%, compared to ADMT's ROE of -0.01%. Regarding short-term risk, RYLPF is less volatile compared to ADMT. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check ADMT's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, USAQ has a market cap of 4.1M. Regarding current trading prices, RYLPF is priced at $25.44, while USAQ trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas USAQ's P/E ratio is 11.17. In terms of profitability, RYLPF's ROE is +0.09%, compared to USAQ's ROE of +0.92%. Regarding short-term risk, RYLPF is less volatile compared to USAQ. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check USAQ's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, RMSL has a market cap of 3.7M. Regarding current trading prices, RYLPF is priced at $25.44, while RMSL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas RMSL's P/E ratio is 0.22. In terms of profitability, RYLPF's ROE is +0.09%, compared to RMSL's ROE of -17961324.55%. Regarding short-term risk, RYLPF is less volatile compared to RMSL. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check RMSL's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, VANIW has a market cap of 3.4M. Regarding current trading prices, RYLPF is priced at $25.44, while VANIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas VANIW's P/E ratio is N/A. In terms of profitability, RYLPF's ROE is +0.09%, compared to VANIW's ROE of -2.64%. Regarding short-term risk, RYLPF is less volatile compared to VANIW. This indicates potentially lower risk in terms of short-term price fluctuations for RYLPF.Check VANIW's competition here

RYLPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RYLPF stands at 24.2B. In comparison, NGMDF has a market cap of 3.3M. Regarding current trading prices, RYLPF is priced at $25.44, while NGMDF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RYLPF currently has a P/E ratio of 21.93, whereas NGMDF's P/E ratio is -0.49. In terms of profitability, RYLPF's ROE is +0.09%, compared to NGMDF's ROE of +0.94%. Regarding short-term risk, RYLPF is more volatile compared to NGMDF. This indicates potentially higher risk in terms of short-term price fluctuations for RYLPF.Check NGMDF's competition here